Millipore Sigma Vibrant Logo

121800 Advanced Glycation Endproduct-BSA

AGE-BSA has been reported to induce apoptosis in cultured human umbilical vein endothelial cells and inhibit nitric oxide synthase activity in proximal tubular epithelial cells.

Advanced Glycation Endproduct-BSA : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: AGE-BSA

View Products on Sigmaaldrich.com
121800
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
121800-10MG
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Flacon en verre 10 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewPrepared by reacting BSA with glycoaldehyde under sterile conditions. Glycated-BSA shows a 5,000 - 10,000% increase in fluorescence as compared to normal BSA (confirmed by fluorescence spectrophotometry, excitation/emission 370/440 nm). AGE-BSA has been reported to induce apoptosis in cultured human umbilical vein endothelial cells and inhibit nitric oxide synthase activity in proximal tubular epithelial cells. Advanced glycation end products and their receptors have been implicated in the pathogenesis of diabetes, induction of proinflammatory cytokines, and stimulation of smooth muscle proliferation, and fibronectin production.
      Catalogue Number121800
      Brand Family Calbiochem®
      SynonymsAGE-BSA
      References
      ReferencesOkamoto, T., et al. 2002. Microvasc. Res. 63, 186.
      Ohgami, N., et al. 2001. J. Biol. Chem. 276, 3195.
      Wang, R., et al. 2001. J. Nippon Med. Sch. 68, 472.
      Sakata, N., et al. 2000. J. Atheroscler. Thromb. 7, 169.
      Verbeke, P., et al. 2000. Biochim. Biophys. Acta 1502, 481.
      Farboud, B., et al. 1999. Mol. Vis. 5, 11.
      Huang, J.-S., et al. 1999. Biochem. J. 342, 231.
      Min, C., et al. 1999. Diabetes Res. Clin. Pract. 46, 197.
      Neumann, A., et al. 1999. FEBS Lett. 453, 283.
      Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun. 256, 549.
      Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol. 20, 83.
      Product Information
      FormLiquid
      FormulationIn sterile-filtered PBS.
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥95% by SDS-PAGE
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      121800-10MG 04055977206197

      Documentation

      Advanced Glycation Endproduct-BSA Certificats d'analyse

      TitreNuméro de lot
      121800

      Références bibliographiques

      Aperçu de la référence bibliographique
      Okamoto, T., et al. 2002. Microvasc. Res. 63, 186.
      Ohgami, N., et al. 2001. J. Biol. Chem. 276, 3195.
      Wang, R., et al. 2001. J. Nippon Med. Sch. 68, 472.
      Sakata, N., et al. 2000. J. Atheroscler. Thromb. 7, 169.
      Verbeke, P., et al. 2000. Biochim. Biophys. Acta 1502, 481.
      Farboud, B., et al. 1999. Mol. Vis. 5, 11.
      Huang, J.-S., et al. 1999. Biochem. J. 342, 231.
      Min, C., et al. 1999. Diabetes Res. Clin. Pract. 46, 197.
      Neumann, A., et al. 1999. FEBS Lett. 453, 283.
      Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun. 256, 549.
      Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol. 20, 83.

      Brochure

      Titre
      Caspases and other Apoptosis Related Tools Brochure
      Pathways and Biomarkers of Oxidative Stress
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision08-April-2008 RFH
      SynonymsAGE-BSA
      DescriptionPrepared by reacting bovine serum albumin (BSA) with glycoaldehyde under sterile conditions. Fluorescence of AGE-BSA is confirmed by fluorescence spectrophotometry, excitation/emission = 370/440 nm. Glycated BSA shows a 5000-10,000% increase in fluorescence compared to control BSA. AGE and their receptors have been implicated in the pathogenesis of diabetes, induction of pro-inflammatory cytokines, and stimulation of smooth muscle proliferation and fibronectin production. AGE-BSA has also been shown to induce apoptosis in cultured human umbilical vein endothelial cells (HUVEC) and inhibit nitric oxide synthase activity in proximal tubular epithelial cells of the kidney.
      FormLiquid
      FormulationIn sterile-filtered PBS.
      Concentration Label Please refer to vial label for lot-specific concentration
      Purity≥95% by SDS-PAGE
      Storage Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Toxicity Standard Handling
      ReferencesOkamoto, T., et al. 2002. Microvasc. Res. 63, 186.
      Ohgami, N., et al. 2001. J. Biol. Chem. 276, 3195.
      Wang, R., et al. 2001. J. Nippon Med. Sch. 68, 472.
      Sakata, N., et al. 2000. J. Atheroscler. Thromb. 7, 169.
      Verbeke, P., et al. 2000. Biochim. Biophys. Acta 1502, 481.
      Farboud, B., et al. 1999. Mol. Vis. 5, 11.
      Huang, J.-S., et al. 1999. Biochem. J. 342, 231.
      Min, C., et al. 1999. Diabetes Res. Clin. Pract. 46, 197.
      Neumann, A., et al. 1999. FEBS Lett. 453, 283.
      Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun. 256, 549.
      Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol. 20, 83.